ArticleThe Lancet regional health. Europe2025
Survival and quality of life after first-time diagnosis of brain metastases: a multicenter, prospective, observational study.
Article in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Clinical Implementation and Oncological Relevance of Molecular Profiling in Brain Metastases Patients-A Multicenter Retrospective Cohort Study.International journal of cancer · 2026Article
- Reprogramming PD-L1 endosomal recycling and lysosomal degradation via engineered exosome-based nanocomposites overcomes immune resistance in lung cancer brain metastasis.Materials today. Bio · 2026Article
- Radiotherapy Modality and Primary Tumor Type as Determinants of Outcomes in Brain Metastases: A Retrospective Study of 734 Patients.Medicina (Kaunas, Lithuania) · 2026Article
- Spatially resolved transcriptomics in human brain metastases identifies macrophage-tumor interactions associated with survival.iScience · 2026Article
- Baseline Graded Prognostic Assessment Is Associated with Postoperative Health-Related Quality of Life Recovery After Brain Metastasis Resection: A Prospective Cohort Study.Journal of clinical medicine · 2026Article
- Living with brain metastases-A longitudinal qualitative study of patient experiences from time of diagnosis.Neuro-oncology practice · 2026Article
- Serum lactate dehydrogenase is associated with the presence and extent of preoperative peritumoral edema in melanoma brain metastases.Journal of neuro-oncology · 2026Article
- Outcomes of hypofractionated stereotactic radiotherapy for brain metastases: do we treat patients or lesions?BMC cancer · 2026Article
- Significance of Positive Cerebrospinal Fluid Cytology (Leptomeningeal Metastasis) in Central Nervous System Metastasis - A Multicentre Clinicopathological Review.Pathology international · 2026Article
- Ionizing Radiation Enhances Prognostically Significant Cellular Immunity Programs in the Brain Metastasis Microenvironment.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Care pathways for asymptomatic brain metastases: comparison of healthcare utilization, costs, and outcomes in outpatient versus acute settings.Journal of neuro-oncology · 2026Article
- Identifying Prognostic Factors in Brain Metastasis Patients Using MRI Morphological Features: A Machine Learning and Survival Analysis Approach.Diagnostics (Basel, Switzerland) · 2026Article
- Adenosine Pathway Activation Defines Genetically Linked Immunosuppressive Subtypes in Solid Tumor Brain Metastases.Cancers · 2026Article
- Regret concerning treatment decisions in patients with primary or secondary brain tumors - a cross-sectional exploratory bicentric analysis.Journal of neuro-oncology · 2026Article
- Cognitive function in long-term survivors after treatment for brain metastases compared with normative samples.Neuro-oncology practice · 2026Article
- Brain Metastasis After Curative Resection of Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.Cureus · 2026Review
- Association between psychological resilience and global health status/quality of life in patients with brain metastases after resection of primary non-small cell lung cancer.Frontiers in psychiatry · 2026Article
- Best supportive care in patients with brain metastases: impact of the primary tumour type on survival.Contemporary oncology (Poznan, Poland) · 2026Article
- Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care.Nature reviews. Clinical oncology · 2025Review
- A balancing ACT: maximizing the benefits of appropriate brain radiation therapy.The Lancet regional health. Europe · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A major concern in anticancer treatment (ACT) of brain metastases (BM) is exposing patients with short expected survival to treatments that negatively impact on quality of life (QoL). Such futile ACT at the end of life is time-consuming and burdensome for patients and their families and entails unnecessary healthcare costs. Refraining from ACT is challenging for both physicians and patients. This study aimed to provide real-life data on survival after BM diagnosis and patient reported outcomes (PROs) after ACT to identify risk factors for futile treatment and to support BM treatment decisions. Methods: This multi-center, prospective, observational study recruited consecutive patients with first-time BM from November 2017 to March 2021. Patients were followed until death or study end (October 1st, 2023). Clinical factors associated with survival were analyzed by the Cox' proportional hazards model. Changes in PROs after BM treatment were described according to Eastern Cooperative Oncology Group (ECOG) performance status, survival, and treatment groups. Findings: For the total cohort ( Interpretation: Patients with ECOG 2-4, especially those with uncontrolled extracranial metastases and ≥5 BM, are at risk for futile ACT. BM treatment guidelines should strongly caution against ACT to patients with expected survival <6 months and specifically advise against WBRT. Funding: The South-Eastern Norway Regional Health Authority; The Norwegian Cancer Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.